4.12
+0(+0.00%)
Currency In USD
| Previous Close | 4.12 |
| Open | 4.11 |
| Day High | 4.18 |
| Day Low | 4.07 |
| 52-Week High | 13.99 |
| 52-Week Low | 2.86 |
| Volume | 791,668 |
| Average Volume | 2.13M |
| Market Cap | 381.81M |
| PE | -8.96 |
| EPS | -0.46 |
| Moving Average 50 Days | 4.28 |
| Moving Average 200 Days | 7.64 |
| Change | 0 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $1,022.33 as of February 21, 2026 at a share price of $4.12. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $319.63 as of February 21, 2026 at a share price of $4.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
GlobeNewswire Inc.
Feb 03, 2026 12:30 PM GMT
Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ETNEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on deve
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
GlobeNewswire Inc.
Jan 13, 2026 12:30 PM GMT
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,